---
document_datetime: 2025-07-16 09:44:22
document_pages: 15
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ilumetri-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: ilumetri-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.5117377
conversion_datetime: 2025-12-22 19:45:03.396511
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ilumetri

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0061              | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                           | 06/02/2025                          | n/a                                         |                                  |           |
| IA/0060              | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol | 30/10/2024                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/10720 /202403   | Periodic Safety Update EU Single assessment - tildrakizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 03/10/2024   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0059                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 01/10/2024   |            | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0058               | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 08/07/2024   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0055               | B.IV.1.c - Change of a measuring or administration device - Addition or replacement of a device which is an integrated part of the primary packaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13/06/2024   | 24/07/2024 | SmPC, Labelling and PL           | The SmPC sections 1, 2, 4.2, 6.4, 6.5, 6.6 and 8 have been updated to include the new presentation Ilumetri 200 mg solution for injection in pre-filled pen (EU/1/18/1323/005). The Labelling and PL have been updated accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0054               | Update of sections 4.8 and 5.1 of the SmPC in order to update the clinical and safety information based on long-term results from the extension periods of the pivotal clinical studies MK-3222-010 (A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), followed by an Optional Long-Term Safety Extension Study, in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)) and MK-3222-011 (A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222 / MK- 3222), followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to- Severe Chronic Plaque Psoriasis). The Product | 16/05/2024   | 24/07/2024 | SmPC, Annex II, Labelling and PL | Eligible patients who completed the double-blind periods of reSURFACE 1(Study MK 3222-P010) and reSURFACE 2 (Study MK-3222- P011) with â‰¥ 50% improvement in PASI from baseline could participate in open-label extension phases of these studies in order to evaluate the long-term safety and maintenance of efficacy of continuous tildrakizumab treatment. Up to 6 years of follow-up data are available. Of the patients who completed the double-blind period, 506 (79%) in reSURFACE 1 and 730 (97%) in reSURFACE 2 entered the extension period. Across studies, at least 76% of patients who had a PASI 90 response at the end of double-blind period, maintained a PASI 90 response during the extension period, when tildrakizumab 100 mg or 200 mg treatment was continued during a period of 192 weeks. The development of neutralizing antibodies to tildrakizumab was associated with lower serum tildrakizumab concentrations. The safety profile of tildrakizumab observed |

<div style=\"page-break-after: always\"></div>

|                     | information is also updated in accordance with the Annex of the excipients guideline. The RMP version 1.4 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | during the long-term extensions periods of reSURFACE 1 and reSURFACE 2 was consistent with that of the double- blind periods. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0052             | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                    | 29/02/2024 | n/a |                                                                                                                                                                                                               |
| IAIN/0056           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                     | 27/02/2024 | n/a |                                                                                                                                                                                                               |
| IAIN/0053           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                     | 09/11/2023 | n/a |                                                                                                                                                                                                               |
| PSUSA/10720 /202303 | Periodic Safety Update EU Single assessment - tildrakizumab                                                                                                                                                                                            | 26/10/2023 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                             |
| IB/0049             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                       | 29/08/2023 | n/a |                                                                                                                                                                                                               |
| IB/0051             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                           | 24/08/2023 | n/a |                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| IA/0050             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                     | 09/08/2023   | 24/07/2024   | Annex II    |                                                                                                                                                                                                                                                                        |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0042              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                           | 25/05/2023   | 24/07/2023   | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Ilumetri in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IA/0047/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 10/05/2023   | n/a          |             |                                                                                                                                                                                                                                                                        |
| IB/0046/G           | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                            | 21/04/2023   | n/a          |             |                                                                                                                                                                                                                                                                        |
| PSUSA/10720 /202209 | Periodic Safety Update EU Single assessment - tildrakizumab                                                                                                                                                                                                                                                       | 14/04/2023   | n/a          |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| IAIN/0045           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                | 06/03/2023   | n/a          |             |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| IA/0044             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                         | 13/02/2023   | n/a        |                        |                                                                                                                                                                                        |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0043             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                     | 31/01/2023   | n/a        |                        |                                                                                                                                                                                        |
| II/0036             | B.IV.1.c - Change of a measuring or administration device - Addition or replacement of a device which is an integrated part of the primary packaging | 26/01/2023   | 24/07/2023 | SmPC, Labelling and PL | The SmPC sections 1, 2, 4.2, 6.4, 6.5, 8, and Annex II has been updated as follows: inclusion of prefilled pen (EU/1/18/1323/004). The Labelling and PL have been updated accordingly. |
| IB/0040             | B.II.z - Quality change - Finished product - Other variation                                                                                         | 08/12/2022   | n/a        |                        |                                                                                                                                                                                        |
| IB/0039             | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                            | 28/10/2022   | n/a        |                        |                                                                                                                                                                                        |
| PSUSA/10720 /202203 | Periodic Safety Update EU Single assessment - tildrakizumab                                                                                          | 27/10/2022   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                      |
| IAIN/0038           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                   | 13/10/2022   | n/a        |                        |                                                                                                                                                                                        |
| N/0037              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                     | 12/10/2022   | 24/07/2023 | PL                     |                                                                                                                                                                                        |
| IA/0035             | A.7 - Administrative change - Deletion of                                                                                                            | 03/08/2022   | n/a        |                        |                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                     | manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                |            |            |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0033             | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                            | 06/07/2022 | n/a        |                                                                                                                                            |
| IB/0034             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                       | 04/07/2022 | n/a        |                                                                                                                                            |
| PSUSA/10720 /202109 | Periodic Safety Update EU Single assessment - tildrakizumab                                                                                                                                                                                                                                                                                                                                        | 22/04/2022 | 20/06/2022 | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10720/202109. |
| IAIN/0031/G         | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 24/05/2022 | n/a        |                                                                                                                                            |
| II/0029/G           | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                | 19/05/2022 | n/a        |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|         | Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method   |            |            |                        | B.I.b.2.d -   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------|
| X/0023  | Extension application to introduce a new strength (200 mg solution for injection). Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                         | 24/02/2022 | 25/04/2022 | SmPC, Labelling and PL |               |
| IB/0030 | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                  | 19/04/2022 | n/a        |                        |               |
| IA/0026 | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                           | 19/11/2021 | n/a        |                        |               |
| IA/0025 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                          | 02/11/2021 | n/a        |                        |               |

<div style=\"page-break-after: always\"></div>

| PSUSA/10720 /202103   | Periodic Safety Update EU Single assessment - tildrakizumab                                                                | 28/10/2021   | n/a        | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------------------|
| IAIN/0024             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                         | 02/07/2021   | n/a        |                                     |
| IB/0019               | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation | 02/06/2021   | n/a        |                                     |
| IB/0021               | B.I.z - Quality change - Active substance - Other variation                                                                | 28/05/2021   | n/a        |                                     |
| IAIN/0020             | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 28/04/2021   | 05/07/2021 | Annex II, Labelling and PL          |
| PSUSA/10720 /202009   | Periodic Safety Update EU Single assessment - tildrakizumab                                                                | 09/04/2021   | n/a        | PRAC Recommendation - maintenance   |
| N/0018                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                           | 08/02/2021   | 05/07/2021 | PL                                  |
| IA/0016               | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure               | 06/11/2020   | n/a        |                                     |
| IB/0015/G             | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation             | 03/11/2020   | n/a        |                                     |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |          |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------|
| PSUSA/10720 /202003 | Periodic Safety Update EU Single assessment - tildrakizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 01/10/2020 | n/a        |          | PRAC Recommendation - maintenance |
| II/0012/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.j - Change in the manufacturer of AS or of a | 23/07/2020 | 05/07/2021 | Annex II |                                   |

<div style=\"page-break-after: always\"></div>

| starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.k - Change in the starting material/reagent/intermediate storage site of MCB and/or B.I.b.2.d - Change in test starting material/reagent/intermediate change to or replacement biological/immunological/immunochemical method or a method using biological AS B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place   |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0014/G           | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                         | 22/07/2020 | n/a |                                   |
| PSUSA/10720 /201909 | Periodic Safety Update EU Single assessment - tildrakizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 17/04/2020 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| II/0010/G           | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS   | 20/02/2020   | n/a   |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10720 /201903 | Periodic Safety Update EU Single assessment - tildrakizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 03/10/2019   | n/a   | PRAC Recommendation - maintenance |
| IB/0009/G           | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                       | 06/09/2019   | n/a   |                                   |
| II/0005/G           | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch                                                                                                                                                                                                                                                                                                                               | 27/06/2019   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

| release/control, and secondary biol/immunol medicinal forms manufactured by processes B.II.b.1.c - Replacement manufacturing site for manufacturing operation(s) release/control, and secondary biol/immunol medicinal forms manufactured by processes B.II.b.1.c - Replacement manufacturing site for manufacturing operation(s) release/control, and secondary biol/immunol medicinal forms manufactured by processes B.II.b.2.b - Change to arrangements and quality Replacement/addition control/testing takes place product and any of the biol/immunol method B.II.b.2.b - Change to arrangements and quality Replacement/addition control/testing takes place product and any of the biol/immunol method B.II.d.2.c - Change in   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                             |            |            |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IA/0008/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 25/06/2019 | n/a        |                        |                                   |
| IAIN/0006           | B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information                                                                                                                                                                                                                                                                                                                           | 31/05/2019 | 04/05/2020 | SmPC, Labelling and PL |                                   |
| PSUSA/10720 /201809 | Periodic Safety Update EU Single assessment - tildrakizumab                                                                                                                                                                                                                                                                                                                                                                                                                                      | 11/04/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| N/0004              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                 | 21/03/2019 | 04/05/2020 | PL                     |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0002   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site   | 23/11/2018   | n/a   |
|-------------|------------------------------------------------------------------------------------------------------|--------------|-------|
| IB/0001/G   | This was an application for a group of variations.                                                   | 23/11/2018   | n/a   |